Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > ARCHIVE
ARCHIVE
- All Applicants Should Be Given Access to Prior Assessment System: JPMA
August 30, 2010
- Terumo: Sales Up 4.9% Driven by Strong Overseas Sales
August 30, 2010
- Fujitsu Aims at 30% Market Share with Cloud Services for Pharma Industry
August 30, 2010
- Asahi Kasei Pharma: Sales Down for Mainstay Products
August 30, 2010
- 80% of Oncologists Conduct KRAS Gene Test: Merck Serono
August 30, 2010
- Miraca HD: Sales Up 10.4% to ¥41.4 Bil.
August 30, 2010
- Torii: Anti-HIV Drug Props Up Business
August 30, 2010
- Korosho to Promote Sharing of Knowhow on Use of Generics
August 30, 2010
- Takara Bio: Gene Engineering Segment Struggles
August 30, 2010
- Yakult: Elplat's Sales Up 31.4%
August 30, 2010
- Sawai: Sales to Dispending Pharmacies Up 59.2%
August 30, 2010
- A&T: Acquisition of ATWill Boosts Sales of In Vitro Diagnostics
August 30, 2010
- New MSD to Start Operation in October
August 30, 2010
- Taiyo Yakuhin: Sales Up 11.2% Despite Plant Shutdown
August 30, 2010
- How to Build a Winning Marketing Team
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
August 30, 2010
- Takeda Considers Acquisition of Overseas Company: Mr Hasegawa
August 30, 2010
- Astellas Ties Up with UMN Pharma to Jointly Develop Flu Vaccines
August 30, 2010
- Korosho to Conduct Large-Scale Trial for Antipsychotics
August 30, 2010
- MTPC Transfers Kerlong to sanofi-aventis
August 30, 2010
- Towa: Direct Sales Ratio Up by More Than 10 Points
August 30, 2010
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…